 Mitoxantrone high-dose etoposide patients relapsed refractory acute leukemia patients relapsed refractory acute myelogenous leukemia AML salvage chemotherapy mitoxantrone IV hour days etoposide days daily infusion daily doses Seven patients mitoxantrone days days median duration initial complete remission CR months patients initial CR months Forty-six percent patients second subsequent salvage attempt patients CR CR course therapy patients patients disease resistant treatment Patients first salvage attempt incidence rate CR second subsequent salvage attempt CR rates patients favorable translocation diploid karyotype patients median survival time months patients months patients CR Mucositis patients Diarrhea rash patients Fever patients documented infections patients patients pancytopenia thrombocytopenia days initiation treatment mitoxantrone high-dose effective antileukemic regimen high incidence mucositis Strategies mucosal damage tolerance combination